The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for chronic lung disease bronchiectasis in the US. The regulator has set a ...

It is estimated that some 300,000 people in the UK have bronchiectasis, a devastating chronic lung condition that causes excess mucus to build up in the lungs, resulting in frequent coughing and ...

Bacterial colonisation is an important predictor of exacerbation in AATD-COPD and may require additional targeted therapy, study suggests.

Patients may experience smoldering lung destruction despite well-controlled ... along with presence of extensive bronchiectasis consistent with ABPA on thoracic radiology after excluding alternate ...

Permanent changes such as bronchiectasis may persist. ABPA: Allergic bronchopulmonary aspergillosis; GINA: Global initiative for asthma. Adapted with permission from [7]. ABPA-S Fulfils the ...